MannKind (MNKD) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vericel (VCEL) has outperformed MannKind (MNKD) over the past year, gaining 17.3% versus a loss of 37.1%. Over five years, VCEL leads with a -21.1% price change compared with -32.8% for MNKD. Vericel is the larger company by market cap ($2.05 billion vs $1.10 billion), about 1.9 times the size.
On valuation, MannKind trades at a lower forward P/E (26.8x vs 47.3x for Vericel).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNKD | VCEL |
|---|---|---|
| Share price | $3.42 | $40.05 |
| Market cap | $1.10B | $2.05B |
| 1-day change | -0.87% | -1.69% |
| YTD return | -39.68% | +11.22% |
| 1-year return | -37.13% | +17.35% |
| 5-year return | -32.81% | -21.15% |
| P/E ratio (TTM) | — | 85.21 |
| Forward P/E | 26.82 | 47.34 |
| EPS (TTM) | $-0.14 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $276.26M |
| Revenue growth (YoY) | — | +16.45% |
| Net income (latest FY) | — | $16.52M |
| Gross margin | — | 74.42% |
| Operating margin | — | 4.00% |
| Net margin | — | 5.98% |
| 52-week high | $6.51 | $49.32 |
| 52-week low | $2.23 | $28.95 |
| Distance from 52-week high | -47.47% | -18.80% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +129.24% | +51.24% |
| Average volume | 4.50M | 507.54K |
| Shares outstanding | 321.54M | 51.21M |
| Employees | 591 | 398 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCEL has outperformed MNKD by 54.5 percentage points over the past year.
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees
MNKD vs VCEL FAQ
Which is bigger, MannKind or Vericel?
Vericel (VCEL) is larger, with a market capitalization of $2.05B compared with $1.10B for MannKind (MNKD).
Which stock has performed better over the past year, MNKD or VCEL?
VCEL returned +17.35% over the past 12 months, compared with -37.13% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are MannKind and Vericel in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for MannKind and Biotechnology: Biological Products (No Diagnostic Substances) for Vericel.